BTK and B-cell chronic lymphocytic leukemia: Vecabrutinib was studied as monotherapy in a phase 1/2 dose escalation and expansion trial for CLL/SLL or non-Hodgkin’s lymphoma, but this was terminated due to suboptimal activity (NCT03037645).13 Fenebrutinib is being studied in autoimmune indications; there are no current clinical trials testing it in hematologic malignancies.14 Preliminary results from the phase 2 dose-expansion study of nemtabrutinib in B-cell malignancies were recently presented, which included 51 CLL/SLL patients of whom 43 (84.3%) had prior BTK inhibitor therapy.